(News Bulletin 247) – AstraZeneca announced on Tuesday that the Chinese authorities had authorized the marketing of Soliris in the treatment of myasthenia gravis, a rare pathology marked by a dysfunction of the immune system.
The pharmaceutical laboratory specifies that the green light from China concerns the generalized and resistant form of the disease in patients expressing anti-acetylcholine receptor antibodies.
AstraZeneca points out that this authorization was based on phase III clinical data showing that Soliris improved the health of individuals in whom immunosuppressive treatments had so far failed.
Soliris, a drug developed by Alexion, the rare disease subsidiary of AstraZeneca, will thus become the first and only inhibitor of
supplement approved for the treatment of myasthenia gravis in China.
The product was previously approved for paroxysmal nocturnal hemoglobinuria (PNH), an extremely rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS).
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
